Ocular Toxicity With New Drugs for Gynecologic Cancers

Antibody-drug conjugates are a promising new option for gynecologic cancers, but they have a variety of ocular or vision-related adverse events that need to be appropriately monitored and managed.
Medscape Medical News

source https://www.medscape.com/viewarticle/990372?src=rss

Comments

Popular posts from this blog

RA and RA-ILD Linked to Higher Lung Cancer Risk

DC’s Harllee Harper Is Using Public Health Tools to Prevent Gun Violence. Will It Work?